6-12 | Médecins Sans Frontières (MSF) released findings from a follow-up survey of its community-based HIV/TB project in Eshowe, KwaZulu Natal.
11-29 | MSF criticises pharma for dragging feet on developing HIV drugs for children 1 December, 2018 is the 30th anniversary of World AIDS Day, ahead of a Vatican City meeting on scaling up HIV diagnosis and treatment for children, the international medical humanitarian organisation Médecins Sans Frontières (MSF) criticised pharmaceutical corporations for their delays and failure to develop appropriate formulations of HIV medicines for children.
10-18 | Kasaye sits on his bed in the intensive care unit of the MSF health centre in Abdurafi, a bottle of soda and some cookies in his hands. He looks incredibly frail and the simple acts of drinking and eating seem to require immense effort. “This is the thirteenth time that I have come to MSF for kala azar treatment,” he says. Kala azar (also known as visceral leishmaniasis) is the second largest parasitic killer after malaria, which makes it one of the most dangerous neglected tropical diseases in the world.
9-25 | Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB As global leaders gather for the first-ever United Nations tuberculosis (TB) Summit in New York this week, Médecins Sans Frontières (MSF)/Doctors Without Borders called on governments to save more lives by scaling up TB testing and treatment today, and make real commitments to develop more effective and easier-to-use tools to defeat TB tomorrow. New global TB figures released last week by
7-23 | As the annual global HIV/AIDS conference gets underway in Amsterdam, Médecins Sans Frontières (MSF) called out ViiV Healthcare—a division of US and UK pharmaceutical corporations Pfizer and GlaxoSmithKline plus Japan’s Shionogi—for preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir. The World Health Organization (WHO) now recommends dolutegravir as a preferred treatment option for adults and for children from four weeks to ten years of age, to replace pediatric treatments containing sub-optima